Cell line · CVCL_0395
Papers236
1 to 20 of 236
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| In vivo validation of intramolecular bivalent glues targeting PSMA reveals potent and tissue-selective BRD4 degradation in prostate cancer. | Acta Pharm Sin B | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The VCPIP1-UBE3A Deubiquitination-Ubiquitination Cascade Contributes to Castration-Resistant Prostate Cancer Progression. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Physiological elasticity and topography modulate in vitro prostate cancer cell behavior. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Profiling crystal engineered ligands for targeting treatment resistant androgen receptors. | Front Pharmacol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cinerascensosides A and B, Two New Cytotoxic Sulfated Saponins From the Sea Cucumber Holothuria cinerascens. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Senolytic Interventions Enhance the Anti-metastatic Activity of Chemotherapy in Prostate Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Castration-resistant prostate cancer cells are addicted to the high activity of cyclin-dependent kinase 2. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sarcosine-Based Pharmacokinetic Optimization and Fluorescent Dye Library Evaluation of Dual-Labeled PSMA Inhibitors for Fluorescence-Guided Surgery. | Pharmaceuticals (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Laron Syndrome Mouse Model Reveals a Potential Contribution of Methylglyoxal-Derived Glycative Stress to IGF-1-Driven Prostate Cancer Progression. | Biology (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer. | Cancer Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CXCR2-mediated metabolic interaction between prostate cancer cells and the immunosuppressive tumor microenvironment. | J Immunother Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| 3beta-HSD1-mediated steroid back-conversion maintains androgen signaling in prostate cancer. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Functional and omics-based rationale for the induction of BRCAness by androgen receptor pathway inhibitors to sensitize prostate cancer to PARP inhibition, regardless of HRR status. | Br J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lactate-induced H3K4me3 histone mark promotes PLOD1-driven prostate cancer invasion. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer. | J Clin Invest | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer. | Oncoimmunology | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3-Directed and PSMA-Directed Bispecific Antibody-Drug Conjugate, for the Treatment of Prostate Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Profiling crystal engineered ligands for targeting treatment resistant androgen receptors. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0395/papers